OKYO Pharma (OKYO) director gets 22,500-share stock award

Rhea-AI Filing Summary

CERRONE GABRIELE M reported acquisition or exercise transactions in this Form 4 filing.

OKYO Pharma Ltd reported that director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, received a grant/award of 22,500 common shares on 2026-07-21 at 1.45 per share. Following this award, his indirect holdings total 10,873,916 common shares.

Insider Trade Summary

Net Buyer: 22,500 shares

Net Buy 1 txn

Insider CERRONE GABRIELE M

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	22,500	$1.45	$33K

Holdings After Transaction: COMMON STOCK — 10,873,916 shares (Indirect, Via Panetta Partners Limited)

Key Figures

Common shares acquired: 22,500 shares Price per share: 1.45 Indirect holdings after transaction: 10,873,916 shares +1 more

4 metrics

Common shares acquired 22,500 shares Non-derivative grant/award on 2026-07-21

Price per share 1.45 Per-share value for the 22,500-share award on 2026-07-21

Indirect holdings after transaction 10,873,916 shares Common stock held indirectly via Panetta Partners Limited

Acquisition transactions reported 1 Single non-derivative grant/award coded as an acquisition

Key Terms

grant/award acquisition, indirect ownership, ten percent owner

3 terms

grant/award acquisition financial

"Transaction coded as a grant/award acquisition of common stock"

indirect ownership financial

"Shares reported as indirect ownership via Panetta Partners Limited"

ten percent owner financial

"Reporting person is identified as a ten percent owner"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/23/2026 - 04:15 PM Accepted by SEC EDGAR 07/23/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What insider transaction did OKYO (OKYO) disclose for Gabriele M. Cerrone?

OKYO disclosed that Gabriele M. Cerrone received a grant/award of 22,500 common shares on 2026-07-21 at 1.45 per share, reported as indirect ownership through Panetta Partners Limited.

How many OKYO (OKYO) shares does Gabriele M. Cerrone hold after this transaction?

After the reported grant, Gabriele M. Cerrone’s indirect holdings total 10,873,916 common shares of OKYO. These shares are held via Panetta Partners Limited, reflecting his position as a director and ten percent owner.

Was the OKYO (OKYO) insider transaction a purchase or a grant?

The transaction was a grant/award acquisition of 22,500 OKYO common shares, coded as an “A” transaction. It is reported as a non-derivative award rather than an open-market purchase or sale.

At what price were the 22,500 OKYO (OKYO) shares awarded to Gabriele M. Cerrone?

The 22,500 OKYO common shares were reported at 1.45 per share. This price applies to the non-derivative grant/award recorded on 2026-07-21 and reflects the transaction’s per-share valuation.

How is Gabriele M. Cerrone’s ownership in OKYO (OKYO) classified?

The reported shares are classified as indirect ownership, held via Panetta Partners Limited. Cerrone is identified as both a director and a ten percent owner of OKYO Pharma Ltd in this context.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CERRONE GABRIELE M

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/21/2026		A		22,500	A	$1.45	10,873,916	I	Via Panetta Partners Limited

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gabriele M. Cerrone	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)